Multiple Myeloma

FDA accepts Iberdomide new drug application for relapsed or refractory multiple myeloma; pharmacists prepare for oral anti-CD38 combos, MRD-driven care.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

FDA approves a new quadruplet therapy for newly diagnosed multiple myeloma, enhancing treatment options for patients ineligible for stem cell transplant.

FDA's draft guidance on MRD and CR as end points accelerates multiple myeloma therapy approvals, enhancing patient access and transforming oncology practices.

Innovative immunotherapy strategies, like linvoseltamab, show promise in treating multiple myeloma, potentially reducing reliance on traditional transplants.

Teclistamab-cqyv shows promising results in treating refractory multiple myeloma, significantly improving survival rates and offering new hope for patients.

New research uncovers why multiple myeloma affects men more than women, highlighting sex-based differences in disease presentation and risk factors.

A new dual-antibody therapy shows promise in treating extramedullary multiple myeloma, offering hope for patients with limited options.

Pharmacists can play a pivotal role in overcoming the many challenges that exist in accessing immunomodulatory drugs in multiple myeloma.

A high-fiber, plant-based diet shows promise in delaying multiple myeloma progression and enhancing metabolism and immune response in patients with precursor conditions.

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

High-dose busulfan-melphalan enhances VRd therapy, improving progression-free survival in high-risk multiple myeloma patients undergoing ASCT.

Mount Sinai's study uncovers how ciltacabtagene autoleucel enhances long-term remission in multiple myeloma by leveraging the patient's immune response.

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

CAR-T and BsAb therapies revolutionize multiple myeloma treatment but pose infection risks, necessitating vigilant monitoring and tailored prevention strategies.

RSV infections in multiple myeloma patients delay treatment but do not increase mortality, highlighting the need for further research on infection management.

Research reveals a notable risk of invasive fungal infections in multiple myeloma patients undergoing BCMA-targeted CAR T-cell therapy, highlighting the need for vigilant monitoring.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.